Biopharma & Life Sciences
Perspective Therapeutics Executive Compensation (FY25)
CATX · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Johan Spoor | Latest say-on-pay support = May 28, 2025 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The Perspective Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 28, 2026Latest filing (DEF 14A): April 16, 2026
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
115 figures on this page: 111 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Johan Spoor: $5,371,889 → $2,404,692 (55.2% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Perspective Therapeutics' chief executive and what were they paid?
Johan Spoor was paid $2,404,692 in total compensation as Chief Executive Officer, Director for fiscal 2025. Spoor's total moved 55.2% lower from the $5,371,889 reported for fiscal 2024.
What was Perspective Therapeutics' say-on-pay result?
Shareholders supported the say-on-pay proposal with 73.7% of votes cast including abstentions in favor at the meeting held May 28, 2025 for fiscal 2024.
Which companies are in Perspective Therapeutics' peer group?
The disclosed peer group includes ALX Oncology, Aura Biosciences, C4 Therapeutics, Caribou Biosciences and CG Oncology, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Lori Woods Former CEO and Director | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | — not reconciled |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Johan Spoor CEO and Director | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Hunt Chief Financial Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Markus Puhlmann Chief Medical Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Lori Woods Former CEO and Director Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Johan Spoor Chief Executive Officer, Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Markus Puhlmann Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Jonathan Hunt Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Johan Spoor Chief Executive Officer, Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Juan Graham Former Chief Financial Officer Departed during or after this year | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Joel Sendek Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Markus Puhlmann Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Joel Sendek | Option | — | — | — | — | — | — | ◇ |
| Johan Spoor | Option | — | — | — | — | — | — | ◇ |
| Juan Graham | Option | — | — | — | — | — | — | ◇ |
| Markus Puhlmann | Option | — | — | — | — | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Joel Sendek | Option | ◇ | — | ◇ | 09/04/2035 |
| Johan Spoor | Option | ◇ | — | ◇ | 03/03/2035 |
| Option | ◇ | — | ◇ | 06/20/2034 | |
| Option | ◇ | — | ◇ | 12/12/2033 | |
| Markus Puhlmann | Option | ◇ | — | ◇ | 03/03/2035 |
| Option | ◇ | — | ◇ | 06/20/2034 | |
| Option | ◇ | — | ◇ | 12/12/2033 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Maya Martinez-Davis | ◇ | — | ◇ | — | — | — | ◇ |
Lori A. Woods Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Heidi Henson | ◇ | — | ◇ | — | — | — | ◇ |
Frank Morich, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert Froman Williamson III | ◇ | — | ◇ | — | — | — | ◇ |
Johan (Thijs) Spoor served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Compensation committee chair | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ALX Oncology ALXO
- Aura Biosciences AURA
- C4 Therapeutics CCCC
- Caribou Biosciences CRBU
- CG Oncology CGON
- Cogent Biosciences COGT
- Day One Biopharmaceuticals DAWN
- Janux Therapeutics JANX
- Kymera Therapeutics KYMR
- Monte Rosa Therapeutics GLUE
- Olema Pharmaceuticals OLMA
- ORIC Pharmaceuticals ORIC
- RAPT Therapeutics RAPT
- Relay Therapeutics RLAY
- Tango Therapeutics TNGX
- Terns Pharmaceuticals TERN
- Tyra Biosciences TYRA
- Y-mAbs Therapeutics YMAB
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2024 | May 28, 2025 | = | ◇ | ◇ | ◇ |
| 2021 | December 13, 2022 | = | ◇ | ◇ | ◇ |
| 2018 | December 10, 2019 | = | ◇ | ◇ | ◇ |
| 2015 | December 14, 2016 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Johan Spoor (Chief Executive Officer, Director), FY2025 total compensation $2,404,692 (base salary $680,000) [exec_comp, SEC accession 0001193125-26-159005, filed 2026-04-16]What this page does not include
Everything above is a fact Perspective Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Perspective Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
115 figures on this page: 111 cited to the filing that reported them, 4 calculated from figures it prints.
111 cited to the filing
4 calculated from the filing
Documents cited
- 0001193125-26-159005Director Compensation · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
- 0000950170-25-078439Proposal 3 – Say on Pay Proposal .
- 0000950170-25-054776Summary Compensation Table
- 0000950170-24-045554Summary Compensation Table
- 0001437749-22-029080Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001437749-19-024428Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001144204-16-140509ITEM 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Perspective Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CATX (accessed 2026).
Short form: data: Velarion
The Perspective Therapeutics brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Perspective Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Perspective Therapeutics discloses
The companies named in CATX's own disclosed peer group.
ALX OncologyAura BiosciencesC4 TherapeuticsCaribou BiosciencesCG OncologyCogent BiosciencesDay One BiopharmaceuticalsJanux TherapeuticsKymera TherapeuticsMonte Rosa TherapeuticsOlema PharmaceuticalsORIC PharmaceuticalsRAPT TherapeuticsRelay TherapeuticsTango TherapeuticsTerns PharmaceuticalsTyra BiosciencesY-mAbs Therapeutics
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}